Igf1 - alec
From Proteopedia
(Difference between revisions)
Line 8: | Line 8: | ||
== Structural highlights == | == Structural highlights == | ||
- | <ref name = 'Alec'> PMID: 20843352 </ref> PMID: 18500379 <ref name = 'Alec'> PMID: 18500379 </ref> | ||
The molecular structure of <scene name='81/814755/Igf1_structure2/2'>IGF-1</scene> tell us many things about the protein itself. Upon inspection of the structure of the IGF-1 protein side by side with <scene name='81/814755/Insulin_structure2/2'>Insulin</scene>, there are three noticeable alpha helixes that are almost identical throughout the backbones of the molecules. The IGF-1 protein, being a relatively small molecule with only sixty-nine amino acids, is larger than the insulin molecule (which only has a 51 amino acid sequence). Because of the relatively small size of these molecules, they are easily transported out of the liver and pancreas into the blood and throughout the body. However, unlike Insulin which is produced and stored as a hexamer containing six Insulin monomers, IGF-1 is produced and stored as a monomer. Because of the structural similarities to Insulin, upon the release of IGF-1 from the liver, it can bind to its own transmembrane receptors on cells but can also bind to the Insulin receptor depending on biological conditions. | The molecular structure of <scene name='81/814755/Igf1_structure2/2'>IGF-1</scene> tell us many things about the protein itself. Upon inspection of the structure of the IGF-1 protein side by side with <scene name='81/814755/Insulin_structure2/2'>Insulin</scene>, there are three noticeable alpha helixes that are almost identical throughout the backbones of the molecules. The IGF-1 protein, being a relatively small molecule with only sixty-nine amino acids, is larger than the insulin molecule (which only has a 51 amino acid sequence). Because of the relatively small size of these molecules, they are easily transported out of the liver and pancreas into the blood and throughout the body. However, unlike Insulin which is produced and stored as a hexamer containing six Insulin monomers, IGF-1 is produced and stored as a monomer. Because of the structural similarities to Insulin, upon the release of IGF-1 from the liver, it can bind to its own transmembrane receptors on cells but can also bind to the Insulin receptor depending on biological conditions. | ||
Line 18: | Line 17: | ||
== Deficiencies == | == Deficiencies == | ||
- | The role of IGF-1 includes a large part in growth of tissues throughout the body, but in the cases of insufficient levels of this protein, the body cannot produce the standard amount of growth experienced by most people. While complications with this protein are relatively rare, the effects of deficiencies in IGF-1 are substantial. When people cannot organically produce Growth Hormone, the term '''Laron Syndrome''' (LS) is given to describe their condition and is an extremely rare diagnosis. Because of their inability to produce GH, there is a correlation with the inability to generate IGF-1 that prevents the body from being able to produce the growth that it needs throughout life. Newborns for instance, if born with LS, are slightly shorter than healthy newborns. Throughout childhood, the child will show a wide range of symptoms. Growth impairment symptoms may include a lack of skeletal maturation, and organ growth including a smaller brain, cardiomicria (small heart), acromicria (small facial, hand and feet bones due to underdevelopment). LS also causes potential for a weakened muscular system which can result in damaged and weakened hair and nails. If left untreated throughout their life, subjects with LS develop dwarfism causing their final height to be between 100 and 145 centimeters, with a highly unproportional upper body to a smaller lower body. However, with treatment, teams have been able to increase the average growth per year in patients with LS. One study showed that daily injections of IGF-1 that is identical to the patient’s own can nearly double the growth of patients in the first year compared to those untreated. The following two years also bring increased growth compared to untreated patients, but not only around 1.5 times. After treatment concluded, some parties reported their patients as reaching a normal final height for their age <ref name = ' | + | The role of IGF-1 includes a large part in growth of tissues throughout the body, but in the cases of insufficient levels of this protein, the body cannot produce the standard amount of growth experienced by most people. While complications with this protein are relatively rare, the effects of deficiencies in IGF-1 are substantial. When people cannot organically produce Growth Hormone, the term '''Laron Syndrome''' (LS) is given to describe their condition and is an extremely rare diagnosis. Because of their inability to produce GH, there is a correlation with the inability to generate IGF-1 that prevents the body from being able to produce the growth that it needs throughout life. Newborns for instance, if born with LS, are slightly shorter than healthy newborns. Throughout childhood, the child will show a wide range of symptoms. Growth impairment symptoms may include a lack of skeletal maturation, and organ growth including a smaller brain, cardiomicria (small heart), acromicria (small facial, hand and feet bones due to underdevelopment). LS also causes potential for a weakened muscular system which can result in damaged and weakened hair and nails. If left untreated throughout their life, subjects with LS develop dwarfism causing their final height to be between 100 and 145 centimeters, with a highly unproportional upper body to a smaller lower body. However, with treatment, teams have been able to increase the average growth per year in patients with LS. One study showed that daily injections of IGF-1 that is identical to the patient’s own can nearly double the growth of patients in the first year compared to those untreated. The following two years also bring increased growth compared to untreated patients, but not only around 1.5 times. After treatment concluded, some parties reported their patients as reaching a normal final height for their age <ref name = 'Laron'> PMID: 11577173 </ref>. Another study on mice showed very similar results upon the intervention of the IGF-1 present in prenatal development. This study showed that as the IGF-1 protein levels are decreased, the weight of the mice upon birth were between sixty and forty-five percent of normal weight of the wild type mice. However, upon intervention on GH during prenatal development, mice with reduced GH were birthed with normal weights <ref name = 'Velloso'> PMID: 18500379 </ref>. These studies show the impact of IGF-1 in the early stages of development and speaks to its importance for growth throughout human life. Although LS is an extremely rare disorder where the body does not organically produce GH of IGF-1, low levels of GH and IGF-1 are much more common in society and have their own treatment options. |
In otherwise normal children and adults, low levels of the protein IGF-1 can result in a range of complications. The deficiency of IGF-1 is typically presented as '''Adult Growth Hormone Deficiency''' (AGHD), which is associated with low levels of GH. Some potential symptoms may include increased sensitivity to temperature, higher body fat percentages, earlier muscle fatigue during exercise, decreased muscle mass, and mental health problems including depression and the feeling of loneliness. This shows the critical importance of balanced levels of IGF-1 in our bodies for our overall well-being. Just as those with Laron Syndrome, there are treatment options that can increase the amount of IGF-1 in the body which are accompanied by decreased risks for mental health and muscular deficiencies. | In otherwise normal children and adults, low levels of the protein IGF-1 can result in a range of complications. The deficiency of IGF-1 is typically presented as '''Adult Growth Hormone Deficiency''' (AGHD), which is associated with low levels of GH. Some potential symptoms may include increased sensitivity to temperature, higher body fat percentages, earlier muscle fatigue during exercise, decreased muscle mass, and mental health problems including depression and the feeling of loneliness. This shows the critical importance of balanced levels of IGF-1 in our bodies for our overall well-being. Just as those with Laron Syndrome, there are treatment options that can increase the amount of IGF-1 in the body which are accompanied by decreased risks for mental health and muscular deficiencies. |
Revision as of 23:19, 2 May 2019
Overview
|
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001 Oct;54(5):311-6. PMID:11577173
- ↑ Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008 Jun;154(3):557-68. doi: 10.1038/bjp.2008.153. PMID:18500379 doi:http://dx.doi.org/10.1038/bjp.2008.153